# US 2012/0251507 A1 · Compositions for preventing cardiac arrhythmia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251507 A1
- Document ID: US20120251507A1
- Status: Published application
- Kind: A1
- Application number: 13/480,140
- Filed: 2012-05-24
- Published: 2012-10-04
- Earliest claimed: 2009-02-18
- Assignees: CorMatrix Cardiovascular, Inc.
- Inventors: ROBERT G. MATHENY; Beecher C. Lewis
- Web page: https://patentgrep.com/patent/US20120251507A1

## CPC

- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61L 27/00: Materials for {grafts or} prostheses or for coating {grafts or} prostheses (dental prostheses A61C13/00; shape or structure of prostheses A61F2/00; use of preparations for artificial teeth A61K6/80; artificial kidneys A61M1/14)
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3637: {characterised by the origin of the biological material other than human or animal, e.g. plant extracts, algae}
- A61L 27/3839: {characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 3/06: Antihyperlipidemics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 2300/236: Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/422: Anti-atherosclerotic agents
- A61L 2300/64: Animal cells
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject.

## Claims

### Claim 1

A method of treating or preventing a cardiac arrhythmia in a subject identified as being at risk of developing a cardiac arrhythmia, comprising administering to the subject a therapeutically effective amount of a biodegradable sponge composition comprising a mammalian extracellular matrix, wherein the biodegradable sponge composition is sandwiched between and in contact with epicardial tissue and pericardial tissue and further comprises at least one of an anti-arrhythmic agent, an anti-inflammatory agent, a lipid-lowering drug, cells, and a protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cells are stem cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the protein is at least one of hyaluronic acid, proteoglycan, and an aminoglycan.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mammalian extracellular matrix is selected from the group consisting of small intestinal submucosa, urinary bladder submucosa, stomach submucosa, liver submucosa, and liver basement membrane.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mammalian extracellular matrix is produced in vitro from culturing mammalian cells.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition further comprises a synthetic extracellular matrix.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mammalian extracellular matrix is selected from the group of tissues consisting of dermis, fascia, pericardium, parenchymal tissue, and myocardial extracellular matrix.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mammalian extracellular matrix is a collagen scaffold from a mammalian tissue source.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cardiac arrhythmia is atrial fibrillation or ventricular fibrillation.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has undergone heart surgery.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has had a myocardial infarction.
